The family team behind Eyes Right Optical have launched their latest venture, promising to bring a new level of style and service to the Australian and New Zealand eyewear sector. Read more
Luxottica supports bushfire-affected communities
Luxottica has pledged to donate up to $150,000 and is offering free replacement spectacles and lubricating eye drops as Australians count the cost of the ongoing bushfire disaster. Read more
Opthea hits recruitment target for diabetic study
Melbourne biopharmaceutical company Opthea has completed the patient recruitment phase for the latest trial of its novel therapy for diabetic macular edema (DME). Read more
French company to acquire Ellex assets in multi-million-dollar deal
Ellex Medical Lasers has agreed to sell its laser and ultrasound business segment to French company Lumibird Group for $100 million. Read more
Zeiss posts tenth consecutive record-breaking year
The Zeiss Group’s Medical Technology segment, as well as its the Vision Care unit, has been announced as a major contributor to the group’s record-breaking financial success over the last year. Read more
Ellex seeks more time to close sale of key business segment
Ellex Medical Lasers has set a new mid-January deadline to complete its ongoing negotiations with a major European group over the sale of its lasers and ultrasound business. Read more
Alcon announces plan for ‘multi-year transformation program’
Alongside its third quarter results for 2019, Alcon has announced a multi-year transformation program to invest in strategic growth initiatives. Read more
Ellex in negotiations to offload lasers and ultrasound
Ellex Medical Lasers is in talks to sell the largest component of its three-pronged business, which accounts for as much as 80% of total revenue. Read more
Uncertainty over common optical business structure after tax ruling
Optometry practices are being urged to review their payroll tax obligations and business structures following a court ruling that could put some healthcare businesses in breach of tax laws. Read more
Australian biotech raises an additional $50 million for AMD drug
Melbourne-based biotech company Opthea has announced it has secured commitments from both Australian and international investors for an additional $50 million to put towards the development of its treatment for neovascular age-related macular degeneration (AMD). Read more